ABBV · News · 20260822N

Guidance / Outlook

AbbVie Inc. · 2026-08-22 · Importance 51 · Surprise 60

Third-party reporting said AbbVie raised its full-year 2026 guidance following reported second-quarter growth. The outlook was supported particularly by immunology medicines SKYRIZI and RINVOQ and by continued diversification beyond the Humira patent cliff. The reports did not provide the revised revenue or earnings amounts, but characterized the update as reinforcing confidence in AbbVie's longer-term growth strategy.

Key facts